

## KDR

**Reactivity:** Human Mouse Rat

**Tested applications:** WB IHC IF IP

**Recommended Dilution:** WB 1:500 - 1:1000 IHC 1:50 - 1:500 IF 1:50- 1:500 IP 1:20- 1:100

**Calculated MW:** 152kDa

**Observed MW:** Refer to Figures

**Immunogen:**

Recombinant Protein of human KDR

**Storage Buffer:**

Store at 4. Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.

**Concentration:**

a

**Synonym:**

FLK1; CD309; VEGFR; VEGFR2

**Catalog #:** A1484

**Antibody Type:**

Monoclonal Antibody

**Species:** Mouse

**Gene ID:** 3791

**Isotype:** IgG

**Swiss Prot:** P35968

**Purity:** Affinity purification

For research use only.

**Background:**

KDR has also been designated as VEGFR-2 (Vascular endothelial growth factor receptor 2), CD309 (cluster of differentiation 309) and Flk1 (fetal liver kinase 1). Vascular endothelial growth factor (VEGF) is a major growth factor for endothelial cells. KDR is one of the two receptors of the VEGF. This receptor, known as kinase insert domain receptor, is a type III receptor tyrosine kinase. It functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting. The signalling and trafficking of this receptor are regulated by multiple factors, including Rab GTPase, P2Y purine nucleotide receptor, integrin  $\alpha V\beta 3$ , T-cell protein tyrosine phosphatase, etc.. Mutations of this gene are implicated in infantile capillary hemangiomas.

**To place an order, please [Click HERE](#).**